Abstract

Background: Acinetobacter baumannii is currently considered one of the greatest causes of nosocomial infection. The rapid emergence and spread of resistance to most conventional antibiotics highlight the need to identify novel antimicrobial agents. Antimicrobial peptides (AMPs) are introduced as potential therapeutic alternatives. Human anionic antimicrobial peptide, dermcidin-1L (DCD-1L), has shown antimicrobial activity against a wide range of nosocomial pathogens; however, it is still unknown whether it exhibits such properties against A. baumannii. Objectives: For the first time, the present study was conducted to examine the antimicrobial activity of DCD-1L against biofilm-forming extensively-drug-resistant (XDR) and pandrug-resistant (PDR) isolates of A. baumannii, belonging to different clonal lineages. Methods: Dermcidin-1L was examined in terms of antimicrobial properties against 1 biofilm-forming representative XDR isolate from each clonal lineage and 1 PDR isolate via minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) analyses and time-kill assay. Dermcidin-1L resistance mutation frequency in A. baumannii was also determined. Results: Minimum inhibitory concentration and MBC of DCD-1L against all 8 representative XDR and standard (ATCC 19606) isolates were 16 and 32 µg/mL, respectively, while the corresponding value for 1 PDR isolate was 8 µg/mL. The time-kill assay results revealed that the bactericidal effects were more rapid against PDR than XDR strains. In addition, the tested AMPs showed a low tendency to develop resistance. Conclusions: The present results showed that DCD-1L exhibits interesting antibacterial properties against PDR A. baumannii strains, making it a promising candidate for the development of new antiinfective therapies.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.